All In Biotech

Drug Trial Radar · NCT07612137

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IBI3005 Combination Therapy in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

282

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.

Conditions

  • Solid Tumor

Interventions

  • IBI3005Drug

    Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)

  • SintilimabDrug

    Anti-PD-1 Monoclonal Antibody

  • Bevacizumab biosimilarDrug

    Recombinant humanized anti-VEGF monoclonal antibody

  • LimertinibDrug

    Third-generation EGFR-TKI

  • OsimertinibDrug

    Third-generation EGFR-TKI

  • CarboplatinDrug

    Second-generation platinum-based chemotherapy drugs

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse eventsTime frame: Up to 3 years
  2. Number of subjects with treatment emergent adverse eventsTime frame: Up to 3 weeks
  3. Number of subjects with adverse events of special interestTime frame: Up to 3 years
  4. Number of subjects with serious adverse eventsTime frame: Up to 3 years
  5. Dose limiting toxicities (DLTs)Time frame: Up to 3 weeks
  6. Number of subjects with clinically significant changes in laboratory tests resultsTime frame: Up to 3 years
  7. Number of subjects with clinically significant changes in physical examination resultsTime frame: Up to 3 years
  8. Number of subjects with clinically significant changes in vital signsTime frame: Up to 3 years
  9. Objective Response Rate, (ORR)Time frame: Up to 3 years
  10. duration of response (DCR)Time frame: Up to 3 years
  11. time to response (TTR)Time frame: Up to 3 years
  12. duration of response (DoR)Time frame: Up to 3 years
  13. progression free survival (PFS)Time frame: Up to 3 years
  14. overall survival (OS)Time frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SunYat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.